Literature DB >> 10489698

Pseudomonas aeruginosa phage lysate as an immunobiological agent. 1. Selection of Pseudomonas aeruginosa clinical strains for phage lysate preparation.

G Sekaninová1, M Kolárová, J Pillich, J Seménka, H Slavíková, D Kubícková, V Zajícová.   

Abstract

A total of 2087 Pseudomonas aeruginosa isolates collected during the period 1994-1997 were used as starting material. Out of 1704 in-patient isolates, 299 strains were selected for the preparation of phage lysates but only five strains provided stable lysates, i.e., maintained the ability to be repeatedly and completely lysed by the appropriate phage in the course of several years. A set of 193 out-patients (189) and water sources (4) isolates failed to yield strains suitable for phage lysate preparation; 190 strains isolated abroad from patients with cystic fibrosis or respiratory infections included three isolates which, despite having a high degree of mucus production, were suitable for lysate preparation. The antigenic pattern of the phage lysates was ascertained by SDS-polyacrylamide gel electrophoresis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10489698     DOI: 10.1007/BF02816229

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN: 0015-5632            Impact factor:   2.099


  31 in total

Review 1.  The crisis in antibiotic resistance.

Authors:  H C Neu
Journal:  Science       Date:  1992-08-21       Impact factor: 47.728

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

Review 3.  Opportunistic nosocomial multiply resistant bacterial infections--their treatment and prevention.

Authors:  E Bergogne-Bérézin; D Decré; M L Joly-Guillou
Journal:  J Antimicrob Chemother       Date:  1993-07       Impact factor: 5.790

4.  The genetic effect of engineered vaccine on Pseudomonas aeruginosa infection in mice.

Authors:  M Nishio; Y Isobe; H Hatano; S Ohno; K Okuda; N Ishii
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

Review 5.  Serogroup and serotype classification of bacterial pathogens.

Authors:  C E Frasch
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

6.  Octavalent Pseudomonas aeruginosa O-polysaccharide-toxin A conjugate vaccine.

Authors:  S J Cryz; J C Sadoff; E Fürer
Journal:  Microb Pathog       Date:  1989-01       Impact factor: 3.738

7.  Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection.

Authors:  M Feldman; R Bryan; S Rajan; L Scheffler; S Brunnert; H Tang; A Prince
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

8.  Predominant pathogens in hospital infections.

Authors:  W R Jarvis; W J Martone
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

Review 9.  Alginate synthesis by Pseudomonas aeruginosa: a key pathogenic factor in chronic pulmonary infections of cystic fibrosis patients.

Authors:  T B May; D Shinabarger; R Maharaj; J Kato; L Chu; J D DeVault; S Roychoudhury; N A Zielinski; A Berry; R K Rothmel
Journal:  Clin Microbiol Rev       Date:  1991-04       Impact factor: 26.132

Review 10.  Bacterial lipases.

Authors:  K E Jaeger; S Ransac; B W Dijkstra; C Colson; M van Heuvel; O Misset
Journal:  FEMS Microbiol Rev       Date:  1994-09       Impact factor: 16.408

View more
  2 in total

Review 1.  Cystic fibrosis therapy: a community ecology perspective.

Authors:  Douglas Conrad; Matthew Haynes; Peter Salamon; Paul B Rainey; Merry Youle; Forest Rohwer
Journal:  Am J Respir Cell Mol Biol       Date:  2012-10-25       Impact factor: 6.914

2.  Efficacy of bacteriophage Lysed Pasteurella marker vaccine in laboratory animal models with a novel DIVA for haemorrhagic septicaemia.

Authors:  Sabia Qureshi; Hari Mohan Saxena
Journal:  Saudi J Biol Sci       Date:  2017-05-05       Impact factor: 4.219

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.